Tuesday, November 29

**9:00-10:30**

**MINICOURSE**

**CONTACT FORCE and NEW TOOLS IN 3D MAPPING SYSTEM**

Chairs: **A. Castro** (Rome, I)

**G. Stabile** (Naples, I)

* Ablation of paroxysmal AF: results from a multicenter experience

**G. Zucchelli** (Pisa, I)

* Which is the best workflow for an efficient and effective AF procedure?

**G. Rovaris** (Monza-MI, I)

* How to predict efficacy and post-ablation recurrences of Atrial Fibrillation

**TBA**

* Map, ablate and validate: Contact Force Technology integrated with 3D Navigation System for effective results in AF

**R. Rordorf** (Pavia, I)

* Usefulness of Robotic Navigation and Contact Force in AF ablation

**G. Fassini** (Milan, I)

* Cardiac biopsy guided by 3D Mapping Systems and intracardiac echo integration

**M. Casella** (Milan, I)

Tuesday, November 29

**9:00-10:30**

**course**

**12 LEAD ECG IN CARDIAC RHYTHM MANAGEMENT**

Directors: **J. Farré** (Madird, E)  
**H.J.J. Wellens** (Maastricht, NL)Tuesday, November 29

**9:00-10:30**

**MINICOURSE**

[**Management of arrhythmias in patients with ACS**](http://click.info.escardio.org/?qs=a97cf31f7a4593a3c20fe3046572f710fc083afd58e0baa32b801ea691f3b705)

Chairs: **P. Serpytis** (Vilnius, LY)  
**M. Tubaro** (Rome, I)

* Amiodarone: is it still the only viable antiarrhythmic agent in the ACS setting?

**TBA**

* Advanced AVB management

**M. Lovric Bencic** (Zagreb, Croatia)

* AF management: pharmacological? Electrical?

**P. Donateo** (Lavagna-GE, PL)

* Ventricular tachycardia: drugs? PTCA? Overdrive?

**A. Ardashev** (Moscow, Russian Federation)

* Relationship between the culprit coronary vessel and type of cardiac arrhythmias

**C. Pristipino** (Rome, I)

* Usefulness of ECG- telemetry in the post-acute phase of ACS

**E. De Maria** (Reggio Emilia, I)

Tuesday, November 29

**9:00-10:30**

**MINICOURSE**

**TIPS FOR A DIFFICULT CRT PROCEDURE,**

**CLINICAL CASES**

Chairs: **G.B. Forleo** (Rome, I)  
**M.C. Giudici** (Iowa City, USA)

* Zero xray to approach a difficult CS ostium: which solutions?

**M. Del Greco** (Rovereto-TN, I)

* When and how use venoplasty?

**E.C. Palma** (New York-NY, USA)

* Large CS branches: which lead?

**A. Quesada** (Valencia, E)

* How and when choose the delivery curve and the lead shape and size?

**H. Zouzou** (Algiers, AL)

* Is Venography of CS always mandatory?

**S. Savastano** (Pavia, I)

* Which signs tell us that is better to stop before we would find in troubles?

**V. Nissardi** (Cagliari, I)

Tuesday, November 29

**9:00-10:30**

**MINICOURSE**

**COMPLEX CASES OF AF MANAGEMENT**

Chairs: **A. Lubinski** (Lodz, PL)  
**D.L. Lustgarten** (Burlington-VT, USA)

* AF and syncope   
  **J.L. Pasquié** (Montpellier, F)
* AF and pulmonary embolism

**M. Rillo** (Taranto, I)

* AF and HF

**G.Q. Villani** (Piacenza, I)

* AF and coronary artery diseases

**S.M. Yashin** (Saint Petersburg, Russian Federation)

* AF and dementia

**D. Malaspina** (Milan, I)

* AF and competitive sport activity

**M. Gwechenberger** (Wien, A)

Tuesday, November 29

**9:00-10:30**

**minicourse**

**HOW TO CRITICALLY INTERPRETE DATA FROM**

**PUBLISHED STUDIES: the ‘NOACs’ EXAMPLE**

**Jointly Organized by ANMCO Research Study Center and SISMEC**

Chairs: **G. Barbati** (Trieste, I)  
**B.M. Cesana** (Brescia, I)

**A.P. Maggioni** (Florence, I)

9:00 – 9:10 Brief introduction of the trials

**A.P. Maggioni** (Florence, I)

***Aristotle:*** Apixaban versus Warfarin in Patients with Atrial Fibrillation

***Rocket:*** Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

***Rely:*** Dabigatran versus Warfarin in Patients with Atrial Fibrillation

***Engage:*** Edoxaban versus Warfarin in Patients with Atrial Fibrillation

9:10 – 9:30 Non-Inferiority studies: Hypothesis to be tested and sample size

calculation

**B.M. Cesana** (Brescia, I)

9:30 – 9:50 Modeling Survival Data: survival and hazard functions

**G. Barbati** (Trieste, I)

9:50 – 10:00 When to do and how to interpret subgroup analyses

**A.P. Maggioni** (Florence, I)

**Discussion**: 10:00 – 10:30

Wednesday, November 29

**9:00-10:30**

**MINICOURSE**

**Left atrial appendage occlusion**

Chairs: **M. La Meir** (Maastricht, NL)  
**C.T. Starck** (Berlin, D)

* Characterization of the appropriate candidate

**G. Speciale** (Rome, I)

* Endocardial systems for LAA occlusion: differences in technique and devices

**G. Vicedomini** (Cotignola-RA, USA)

* Epicardial ligation of LAA: benefits and complications

**A.S. Revishvili** (Moscow, Russian Federation)

* Left atrial appendage ligation as a mechanism for rhythm control

**J. Melichercik** (Lahr, D)

* Long term follow up of patients submitted to LAA occlusion or ligation

**C. Amellone** (Ciriè-TO, I)

* Endocardial occlusion of left atrial appendage to treat incomplete surgical LAA ligation

**P. Della Bella** (Milan, I)

Tuesday, November 29

**11:00-12:30**

**FORUM ON REMOTE CONTINUOUS MONITORING**

**Session II**

**ILR: Beyond syncope**

Chairs: **V. Di Lazzaro** (Rome, I)

**J. Schreieck** (Tübingen, D)

* Are we ready for looking beyond syncope?

**A. Ungar** (Florence, I)

* ILR for early detection of atrial fibrillation

**T. Infusino** (Catanzaro, I)

* ILR post atrial fibrillation ablation

**TBA**

* ILR for cryptogenic stroke

**TBA**

* ILR in inherited cardiac arrhythmia disease

**TBA**

* Available technologies for a simple, precise, reliable monitoring

**TBA**

Tuesday, November 29

**11:00-12:30**

**course**

**12 LEAD ECG IN CARDIAC RHYTHM MANAGEMENT**

Directors: **J. Farré** (Madird, E)  
 **H.J.J. Wellens** (Maastricht, NL)

Tuesday, November 29

**11:00-12:30**

**WHAT’S NEW IN THE RISK ASSESSMENT OF ATRIAL FIBRILLATION?**

Chairs: **R. De Ponti** (Varese, I)

**D.T. Martin** (Burlington-MA, USA)

* Correlation between P-wave duration and the risk of atrial fibrillation

**F. Perna** (Rome, I)

* Correlation between supraventricular ectopic activity and incidence of atrial fibrillation

**F. Bello Morgado** (Lisbon, P)

* Correlation between Body weight and incidence of AF

**D.I. Vanegas** (Bogota, Colombia)

* Correlation between ACS and Atrial fibrillation: is it the type of ACS determinant?   
  **TBA**
* Correlation of Obstructive Sleep Apnea and Atrial Fibrillation Recurrence

**M.T. La Rovere** (Montescano-PV, I)

* Atrial fibrillation in hypertrophic cardiomyopathy

**C. Autore** (Rome, I)

Tuesday, November 29

**11:00-12:30**

# [Risk markers of sudden death on the 12-lead ECG](http://mail.elsevierhealth.com/cgi-bin23/DM/x/n4Up0IqcYL0INz0BTzZt0Ef)

Chairs: **K. Aonuma** (Tsukuba, JP)

**E. Pérez Pereira** (Madrid, E)

* Vector analysis of electrocardiogram in assessment of risk of sudden cardiac death (SCD) in arrhythmogenic right ventricular  
  dysplasia/cardiomyopathy

**TBA**

* Substrate of electrocardiographic abnormalities and life-threatening arrhythmias in Takotsubo cardiomyopathy

**A. Pani** (Milan, I)

* Predicting SCD through ECG in Heart Failure patients: new methods

**P. Matusik** (Krakow, PL)

* New insight in ECG diagnosis of Brugada syndrome

**A. Al Fagih** (Riyadh, SA)

* Ventricular ectopic beats as predictor of HF and death

**C. Bisceglia** (Milan, I)

* New insight in ECG diagnosis of Long QT syndrome and Short QT syndrome

**P. Zartner** (Sankt Augustin, D)

Tuesday, November 30

**11:00-12:30**

**Ambulatory heart failure treatment guided by pulmonary artery pressure monitoring**

Chairs: **N. Aspromonte** (Rome, I)  
**TBA**

* Why to monitor continuously pulmonary artery pressure in heart failure patients?  
  **M.R. Cowie** (London, UK)

* Material, implant technique and follow-up  
  **G.B. Perego** (Milan, I)
* Changes in medical therapy guided by pulmonary artery pressure monitoring  
  **TBA**
* Does continuous monitoring of pulmonary artery pressure reduce hospitalizations for heart failure?  
  **TBA**

* Trouble and troubleshooting of the system  
  **TBA**
* Cost – effectiveness of ambulatory monitoring of pulmonary artery pressure  
  **TBA**

Tuesday, November 29

**11:00-12:30**

**MINICOURSE**

**cardiac arrhythmogenesis**

Chairs: **K.H. Kuck** (Hamburg, D)

**TBA**

* Mechanism

**M. Tritto** (Castellanza-VA, I)

* Genetic markers and SCD

**R. Mango** (Rome, I)

* Neurovegetative balance and arrhythmogenesis

**A. Rossillo** (Mestre-VE, I)

* Arrhythmogenesis in structural heart diseases

**D. Lin** (Philadelphia-PA, USA)

* The link between extracardiac diseases (o comorbidity) and arrhythmogenesis

**TBA**

* STEM CELLS: current role and future perspectives

**E.U. Alt** (Houston-TX, USA)

Tuesday, November 29

**11:00-12:30**

**arrhythmias in sport practice**

Chairs: **A. Biffi** (Rome, I)  
**Y. Kondo** (Chiba, JP)

* Effects of chronic exercise on atrial and ventricular remodelling

**TBA**

* Does exercise favours sudden death?

**TBA**

* Should we stop an athlete with frequent premature ventricular beats and apparently normal heart?

**C.C. De Cock** (Amsterdam, NL)

* Role of MRI in solving discrepancies between an abnormal ECG and a normal Echocardiogram in the athlete

**S. Aquilani** (Rome, I)

* Can we allow an athlete with ICD to continue sport practicing  
  **J. Koyama** (Kumamoto City, JP)
* Could a perfect rescue organization increases eligibility for competitive sports?

**M.R. Squeo** (Rome, I)

Tuesday, November 29  
**12:30-14:00**

**“STATE OF THE ART” LECTURES**

Chairs: **M. Di Biase** (Foggia, I)

**S.G. Priori** (Pavia, I)

* Atrial fibrillation ablation **A. Natale** (Austin-TX, USA)

* Idiopathic VF: mechanisms and new perspectives **M. Haissaguerre** (Bordeaux, F)

Tuesday, November 29

**12:30-14:00**

**DEBATES**

Chairs: **J. Borbola** (Budapest, H)  
**G.F. Van Hare** (St. Louis-MI, USA)

* Cardiac contractility modulation is cost-effective in HF patients
* PROS

**C. Tschöpe** (Berlin, D)

* CONS

**F. Laurenzi** (Rome, I)

* CRT is cost-effective also in pediatric patients
* PROS

**G.F. Van Hare** (St. Louis-MI, USA)

* CONS

**T. Karagoz** (Ankara, TR)

Tuesday, November 29

**12:30-14:00**

**DEBATES**

Chairs: **P.G. Guerra** (Montreal, CDN)  
**E. Mikhaylov** (St. Petersburg, Russian Federation)

* Laser energy should be preferred to radiofrequency for atrial fibrillation ablation
* PROS

**TBA**

* CONS

**TBA**

* Crio Energy should not be used for ablation of persistent atrial fibrillation
* PROS

**T. Vogtmann** (Postdam, D)

* CONS

**TBA**

Tuesday, November 29

**14:00-15:30**

**Cardiac resynchronization therapies: clinical issues**

Chairs: **A. Auricchio** (Lugano, CH)

**M. Lunati** (Milan, I)

* Predicting response to CRT: the VALID risk score   
  **M. Gasparini** (Rozzano-MI, I)
* Adaptive CRT pacing in patients with normal AV conduction and LBBB  
  **TBA**
* New algorithms to correctly calculate effective biventricular pacing  
  **A. Vincenti** (Sesto S. Giovanni-MI, I)
* Relationships between LV activation time and CRT outcomes   
  **M. Biffi** (Bologna, I)
* Prognostic implications of functional mitral regurgitation in CRT patients  
  **K. Sedlacek** (Prague, CZ)
* Multisite pacing for cardiac resynchronization therapy: are there different benefits according the underlying pathology?   
  **TBA**

Tuesday, November 29

**14:00-15:30**

**EURO-JAPAN ARRHYTHMIA FORUM (EJAF)**

**Session III**

**AF clinical long term follow up**

Chairs: **K. Matsumoto** (Saitama, JP)  
**P. Sommer** (Leipzig, D)

* Development of cognitive impairment in AF patients  
  **TBA**
* How does asymptomatic AF after ablation influence mortality?  
  **T. Yamane** (Tokyo, JP)
* Can echocardiographic parameters predict outcomes in AF ablation?  
  **S. Takatsuki** (Tokyo, JP)

• Targeting rotors as an AF Ablation Strategy – is it effective?  
**TBA**

• New Technology Discussion; The use of the MediGuide system to reduce dangerous radiation exposure to physicians, patients and hospital staff  
**K. Soejima** (Tokyo, JP)

Tuesday, November 29

**14:00-15:30**

# bORDERLINE iNDICATIONS TO ICD

Chairs: **J.J. Blanc** (Brest, F)

**Y. Al Hebaishi** (Riyadh, SA)

* ICD implant in children

**M.S. Silvetti** (Rome, I)

* ICD implant in “grand-old” patients  
  **TBA**
* ICD implant in patients on dialysis

**F. Vetta** (Rome, I)

* In oncologic patients

**C. Pignalberi** (Rome, I)

* In psychiatric patients

**K. Seidl** (Ingolstadt, D)

* As a bridge to heart transplantation

**S. Ferretto** (Padua, I)

Tuesday, November 29

**14:00-15:30**

**REFLEX SYNCOPE**

Chairs: **F. Ammirati** (Rome, I)

**P.E. Vardas** (Heraklion, GR)

* Tilt test: the way you do it makes the difference

**L. Fusé** (Milan, I)

* Tilt testing: for diagnosis or for stratification?

**R.A. Kenny** (Dublin, Ireland)

* Carotid sinus syndrome and vasovagal syncope: to pace or not to pace

**D.G. Benditt** (Minneapolis-MN, USA)

* Which is the best pacing strategy?  
  **V. Zacà** (Siena, I)
* Which sensors and algorithms may be helpful for a more effective and pshysiological pacing in NM Syncope?

**E. Occhetta** (Novara, I)

* How programming pacemakers in neurally mediated syncope?

**T. Ishikawa** (Yokohama, JP)

Tuesday, November 29

**14:00-15:30**

**NEW INSIGHTS ON INHERITED ARRHYTHMOGENIC DISEASES TREATMENT**

Chairs: **M. Haissaguerre** (Bordeaux, F)

**S.G. Priori** (Pavia, I)

* The role of Ic drugs for treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

**V. Altamura** (Rome, I)

* Cathether ablation therapy for Idiopathic ventricular fibrillation

**M. Scanavacca** (Sao Paolo, BR)

* Ablation in Brugada syndrome: is fenotype regression enough?

**G. Brugada** (Barcelona, E)

* Left Cardiac Sympathetic Denervation outcomes in channelopathies

**P.J. Schwartz** (Milan, I)

* Eligibility of S-ICD in inherited arrhytmogenic diseases

**F. Migliore** (Padua, I)

* Is an aggressive treatment justified by long term follow-up in channelopathies?

**F. Del Carpio** (Rochester-MN, USA)

Tuesday, November 29

**14:00-15:30**

**CATHETER LESION FORMATION IN ATRIAL FIBRILLATION ABLATION**

Chairs: **T. Dickfeld** (Baltimore-MD, USA)  
**A. Nogami** (Tsukuba, JP)

* Left atrial structure and physical vulnerability

**A. Buiatti** (Munich, D)

* Lesions obtained by RF non-irrigated catheters: whose and how?

**F. Guarracini** (Trento, I)

* Lesions obtained by RF irrigated catheters: when and how?

**S. Grossi** (Turin, I)

* Lesions obtained by Contact Force Catheters

**M. Wright** (London, UK)

* Lesions obtained by Cryoenergy catheters

**G.B. Chierchia** (Brussels, B)

* Lesions obtained by laser energy catheters

**TBA**

Tuesday, November 29

**14:00-15:30**

**WOMEN IN ELECTROPHYSIOLOGY**

Chairs: **S. Fichtner** (Munich, D)

**M. Gwechenberger** (Wien, A)

* Are the female electrophysiologists undervalued?

**S. Fichtner** (Munich, D)

* Is the acceptance of the general patient population lower than for men?

**T.C.A. Lobban** (Stratford Upon Avon, UK)

* Is the access to the EP lab for training more difficult than for men?

**G. Domenichini** (London, UK)

* Their scientific production and publications is percentually lower, similar or higher than men?

**G. Pelargonio** (Rome, I)

* Why the majority of female cardiologists do not select electrophysiology as preferred subspecialty work?

**V.I. Calvi** (Catania, I)

* Is still useful to continue to discuss generically and not only individually on female electrophysiologist?

**G. Turitto** (Brooklyn-NY, USA)

Tuesday, November 29

**14:00-15:30**

**SubQ-ICD: SPECIAL ISSUES**

Chairs:  **B. Lemke** (Luedenscheid, D)  
**K. Okumura** (Kumamoto, JP)

* Leadless pacemakers and subcutaneous ICD: may they talk to each other?

**L. Sciarra** (Rome, I)

* Is the Subcutaneous Implantable Cardioverter-Defibrillator compatible with other Cardiac Implantable Electronic Devices?

**S. Viani** (Pisa, I)

* Is the Subcutaneous Implantable Cardioverter-Defibrillator compatible with catheter-based therapies including cardiac contractility modulation (CCM) and vagus nerve stimulation (VNS)?   
  **H. Schmidinger** (Wien, A)
* The role of subcutaneous ICD in patients with congenital heart diseases

**B. Sarubbi** (Naples, I)

* S-ICD as an alternative in patients with documented VF or not tolerated VT after MI

**P. Ferrari** (Bergamo, I)

|  |
| --- |
| * [Where does the subcutaneous ICD fit in my patient practice](http://click.info.escardio.org/?qs=ac3c3aa2efddfb4b9c4fdc8ea2b7cf5f7acf94e8f6d0e7a94a61d737f1c88eeb)? |

**H. Bonnemeier** (Kiel, D)

Tuesday, November 29  
**15:30-17:00**

**Late evidences of clinical research in cardiac pacing**

Chairs: **A. Capucci** (Ancona, I)  
**TBA**

* Are DDD/AAI mode switch algorithms worthwhile to prevent un-necessary ventricular pacing and improve patient outcome?   
  **V. Calvi** (Catania, I)
* The lacking proof of the benefit of physiological heart rate modulation in sick sinus syndrome: the role of new studies  
   **J.G. Martinez** (Alicante, E)
* What is the real access to MRI examination of the current population with MRI conditional device? The REALLY Pro MRI results  
  **TBA**
* What is the real impact of automatic capture algorithms on device longevity? The results of the ESSENTIAL registry  
  **G. Boriani** (Modena, I)
* Which is the ideal ICD in Brugada Syndrome?   
  **G. Vicedomini** (S. Donato Milanese-MI, I)
* Challenging the class II-B indication of cardiac pacing in reflex syncope with positive tilt test: the BIOSync CLS study  
  **M. Brignole** (Lavagna-GE, I)

Tuesday, November 29

**15:30-17:00**

**EURO-JAPAN ARRHYTHMIA FORUM (EJAF)**

**Session IV**

**Ablation of ventricular tachycardia**

Chairs: **R. Schilling** (London, UK)  
**H. Tada** (Fukui, JP)

* Epicardial ablation in non-ischemic VT   
  **K. Soejima** (Tokyo, JP)
* The importance of hybrid approaches when treating VT  
  **TBA**
* Present and future of advanced ventricular mapping   
  **C. Lavalle** (Rome, I)
* Can urgent catheter ablation improve mortality in patients with acute heart failure and recurrent ventricular fibrillation?  
  **M. Hayashi** (Tokyo, JP)
* New Technology Discussion: New and improved 3D Mapping and Advanced Tools to increase the efficacy of VT Ablation  
  **J. Moreno** (Madrid, E)

Tuesday, November 29

**15:30-17:00**

**NEW DIRECTIONS IN AF ABLATION**

Chairs:  **C. Tondo** (Milan, I)  
**TBA**

* New strategies in AF ablation after more than 10 years of experience with the cryoballoon catheters

**G. Stabile** (Naples, I)

* Take home messages from the most recent clinical trials and registries on cryo AF ablation

**M. Mantica** (Milan, I)

* Early cryoablation as first line treatment for AF: what’s new?

**S. Iacopino** (Cotignola-RA, I)

* The role of cryo one-shot technologies for persistent AF

**S. Boveda** (Toulouse, F)

* Long term results of phased-RF technologies: what can we say after 10 years?

**TBA**

* The role of non-invasive cardiac mapping system: the Bordeaux experience with CardioInsight

**TBA**

Tuesday, November 29

**15:30-17:00**

**ENDOPOINTS TO EVALUATE THE EFFICACY OF VENTRICULAR TACHYCARDIA ABLATION**

Chairs: **M. Borrgrefe** (Mannheim, D)

**C. Pandozi** (Rome, I)

* Early post-ablation VT inducibility **A. Scopinaro** (Alessandria, I)

* Predischarge, non invasive programmed stimulation (NIPS) in ICD recipients  
  **P. Vergara** (Milan, I)
* Abolition of fragmented and late potentials  
  **TBA**

* Unipolar endocardial mapping to predict VT ablation efficacy in ischemic and non ischemic patients  
  **T. Deneke** (Bad Neustadt, D)
* Does reaching the VT ablation endopoints allow us not to implant an ICD?  
  **C. De Chillou** (Nancy, F)
* VT ablation in GUCH patients  
  **TBA**

Tuesday, November 29

**15:30-17:00**

**Cardiac resynchronization therapies: outcomes**

Chairs: **M.M. Gulizia** (Catania, I)  
**TBA**

* Reduction of ventricular arrhythmias and shock burden by CRT-D with quadripolar leads  
  **K. Ando** (Kitakyushu, JP)
* Multisite pacing in CRT: rationale and solutions

**G. Mascioli** (Bergamo, I)

* Multipoint strategies and advanced rate modulation: which added value in CRT?  
  **D. Spaziani** (Magenta, I)
* Atrial pacing in CRT. Is it always needed? Which is the role of single pass VDD in CRT?

**M. Biffi** (Bologna, I)

* CRTD full body MRI and quadripolar lead: is there a real advantage for HF patients?**A. Peralta** (Chestnut-MA, USA*)*
* Impact of battery longevity on CRT outcome

**G. Morani** (Verona, I)

Tuesday, November 29

**15:30-17:00**

### VT ABLATION: sTAtE OF THE ART.

### IS VT ABLATION CHALLENGING YOUR VIEW?

Chairs:  **R. De Ponti** (Varese, I)

**M. Scaglione** (Asti, I)

* VT ablation: clinical practice and current evidence

**P. Della Bella** (Milan, I)

* Ventricular tachycardia ablation and substrate modification: how it is changing our workflow

**J. Silberbauer** (London, UK)

Tuesday, November 29

**15:30-17:00**

**LEAD EXTRACTION: WHICH IS THE BEST WAY**

Chairs: **C. Ermis** (Antalya, TR)  
**A. Kutarski** (Lublin, PL)

* Risk score to predict adverse events in lead extraction

**A. Polewczyk** (Kielce, PL)

* Usefulness of intravascular ultrasound to predict potential troubles in lead extraction

**E. Soldati** (Pisa, I)

* Need of a surgical rescue for catastrophic complications of lead extraction

**G.H.R. Moosdorf** (Marburg, D)

* Extraction of superfluous device leads: pros and cons

**M. Shoda** (Tokyo, JP)

* Should we use the antibacterial ”Pouch” during the new device implantation after lead explant?

**A. Fagagnini** (Rome, I)

* Follow-up pf patients without reimplantation after lead extraction

**D. Freire** (Montevideo, ROU)

Tuesday, November 29

**15:30-17:00**

**ARRHYTHMIC BURDEN IN cardiomyopathies**

Chairs: **A. Schirdewan** (Berlin, D)

**S. Zhang** (Beijing, Republic of China)

* Cardiac Amylodosis

**F. Pentimalli** (Savona, I)

* Cardiac Sarcoidosis

**D.T. Martin** (Burlington-MA, USA)

* Takotsubo

**N. Fragakis** (Thessaloniki, GR)

* HCM

**B. Pezzulich** (Turin, I)

* DCM

**E. Boschetti** (Terni, I)

* Non compacted myocardium

**N. Cabanelas** (Coimbra, P)

Tuesday, November 29

**17:30-19:30**

**OPENING CEREMONY**

17:30 Welcome Address

Congress Chairmen  
**M. Santini  
L. Santini**

Scientific Societies

18:30 Magistral Lecture

* From Drug repositioning to gene therapy: taking channelopathies beyond   
  beta-blockers  
  **S.G. Priori** (Pavia, I)

Wednesday, November 30

**9:00-10:30**

**HOW TO STRATIFY CANDIDATES FOR ICD IMPLANTATION IN PRIMARY PREVENTION**

Chairs: **D. Igidbashian** (Gorizia, I)

**TBA**

* Is EF still enough?

**D. Andresen** (Berlin, D)

* Differences between ischemic and non ischemic patient population

**A. Pozzolini** (Pesaro, I)

* Is still appropriate to delay the ICD implant after revascularization?

**L.J.L.M. Jordaens** (Gent, B)

* Do we have new available markers for a non invasive stratification of SD risk?

**W. Amara** (Paris, F)

* An update on the role of the EP study in risk stratification

**G. De Martino** (Bari, I)

* Future perspectives

**G. Turitto** (Brooklyn-NY, USA)

Wednesday, November 30

**9:00-10:30**

**CARDIAC PACING TO TREAT ATRIAL FIBRILLATION**

Chairs: **G. Boriani** (Modena, I)

**A.S. Manolis** (Athens, GR)

* DDD, MVP or DDDRP+MVP: which is the optimal pacing mode in sick sinus syndrome ? The results of the MINERVA trial

**L. Padeletti** (Florence, I)

* Minimization of ventricular pacing may reduce persistent atrial fibrillation. Results from SavePace, Prefer MVP and MINERVA trials

**TBA**

* Atrial antitachycardia pacing to interrupt atrial flutter and atrial tachycardia in patients with implanted devices

**G.B. Perego** (Milan, I)

* The need for AF detection through CIEDs

**G. Molon** (Negrar-VR, I)

* A new single chamber ICD for effective AF monitoring

**G. Rovaris** (Monza-MI, I)

* The current role of “Ablate and Pace” should we use it more or less?  
  **G.L. Botto** (Como, I)

Wednesday, November 30

**9:00-10:30**

# Screening patients with suspected or known ventricular arrhythmias

Chairs: **A. Ardashev** (Moscow, Russian Federation)

**C. Lavalle** (Rome, I)

* Molecular autopsy and prevention of sudden death: a new must for cascade familial screening

**G. Thiene** (Padua, I)

* Screening patients with suspected or known ventricular arrhythmias: all the roads bring to ECG monitoring   
  **P.M.G. Agricola** (Crema-CR, I)
* Screening patients with suspected or known ventricular arrhythmias: the role of exercise stress testing

**J.K. Wranicz** (Lodz, PL)

* Screening patients with suspected or known ventricular arrhythmias: the role of imaging

**C. Martignani** (Bologna, I)

* Screening patients with suspected or known ventricular arrhythmias: the role of EP study and ablation

**L. Aguinaga** (Buenos Aires, RA)

* Which is the correct time for revaluation of LVEF after MI to assess the potential need for primary prevention ICD implantation?

**A. Ronaszéki** (Nice, F)

Wednesday, November 30

**9:00-10:30**

**use of noac in arrhythmologic out patient setting**

Chairs: **G. Di Pasquale** (Bologna, I)

**TBA**

* “NOAC in the pocket” and “Check your pulse” strategy

**J. Abboud** (Beirut, RL)

* NOAC and Telecardiology

**E. Menardi** (Cuneo, I)

* NOAC and ILR

**D. Poçi** (Orebro, S)

* NOAC and AF detected by implanted devices at in-office follow up

**N. Reyes Reyes** (San Andres Cholula, MEX)

* NOAC and AF detected by implanted devices at remote monitoring

**TBA**

* The importance of education and patients’ counselling to improve NOAC adherence in non valvular AF patients

**A. Aiello** (Rome, I)

Tuesday, November 30

**9:00-10:30**

**CATHETER ABLATION OF ATRIAL FIBRILLATION: COMPLICATIONS**

Chairs: **L. Di Biase** (Austin-TX, USA)

**R. Kobza** (Luzern, CH)

* Incidence of esophageal lesions post atrial fibrillation ablation

**D. Cavaco** (Carnaxide, P)

* The use of esophageal temperature probes: an helpful tool or a risk factor?

**M. Santamaria** (Campobasso, I)

* The “stiff left atrial syndrome” post atrial fibrillation ablation

**TBA**

* “Gastropareris”: an underestimated complication post atrial fibrillation ablation **G. Sirico** (Milan, I)
* The risk of stroke post atrial fibrillation ablation Vs transthoracic electrical cardioversion

**F. Vassanelli** (Brescia, I)

* Frequency of fatal outcomes after atrial fibrillation ablation

**S. Matsuo** (Tokyo, JP)

Wednesday, November 30

**9:00-10:30**

**MIDTERM BENEFITS OF SPECIAL PACEMAKER IMPLANTATION TECHNIQUES**

Chairs: **B. Sassone** (Cento-FE, I)  
**TBA**

* Incremental survival benefit with quadripolar lead and multipoint pacing for CRT

**F. Zanon** (Rovigo, I)

* Left ventricular septal pacing for anti-bradycardia pacing

**F. Prinzen** (Maastrict, NL)

* Triventricular pacing for CRT

**G. Zingarini** (San Sisto-PG, I)

* Left ventricular leadless pacemaker: pros and cons

**TBA**

* Mid-term right ventricular leadless pacemaker explantation: feasible dangerous?

**R.E. Knops** (Amsterdam, NL)

Wednesday, November 30

**9:00-10:30**

**SLEEP APNEA AND CARDIAC ARRHYTHMIAS**

Chairs: **E. Bloch-Thomsen** (Aalborg, DK)  
**TBA**

* Mechanisms underlying arrhythmias in sleep apnea

**M. Braghiroli** (Veruno-NO, I)

* Arrhythmias in heart failure patients with sleep apnea

**K. Aonuma** (Tsukuba, JP)

* Impact of sleep apnea on atrial fibrillation ablation

**J. Marti-Almor** (Barcelona, E)

* Usefulness of sleep apnea continuous monitoring by implanted devices

**M. Giaccardi** (Florence, I)

* Influence of the sleep apnea treatment on cardiac arrhythmias

**TBA**

* Implanted devices to treat sleep apnea

**P. Defaye** (Grenoble, F)

Wednesday, November 30  
**11:00-12:30**

**Home Monitoring: just monitoring or  
therapy?**

Chairs: **R.P. Ricci** (Rome, I)  
**T. Szili-Torok** (Rotterdam, NL)

* Home Monitoring and reduction of all cause mortality in HF: the IN-TIME Study  
  **G. Hindricks** (Leipzig, D)
* Worsening heart failure predictor: a hype or a dream? Lessons from SELENE HF Study  
  **L. Calò** (Rome, I)
* How do home monitoring indexes trend before death? Insight Home Guide data  
  **A. D’Onofrio** (Naples, I)
* Which is the best timing for VT ablation in ICD recipients: the PARTITA trial   
  **P. Della Bella** (Milan, I)
* Is a ‘model free’ approach an option towards reliable worsening heart failure prediction?  
  **E.G. Gronda** (Sesto S. Giovanni-MI, I)
* Reduction of inappropriate therapies in ICD population through Home Monitoring: lessons from the ECOST and its clinical application  
  **N. Sadoul** (Vandoeuvre Les Nancy, F)

Wednesday, November 30

**11:00-12:30**

**FORUM ON ATRIAL FIBRILLATION**

**Session I**

**Clinical management of atrial fibrillation**

Chairs: **L. Bianconi** (Rome, I)

**S. Levy** (Marseille, F)

* Digoxin associated mortality: how to control the heart rate in atrial fibrillation patients?

**S. Koulouris** (Bayreuth, D)

* Trasthoracic electrical cardioversion of atrial fibrillation in patients under NOAC: should we behave differently than usual?

**TBA**

* How to reduce ERAF after electrical cardioversion of atrial fibrillation

**E. Aliot** (Vandoeuvre-lès-Nancy, F)

* Can we apply the “Pill in the pocket” technique also to NOAC for paroxysmal atrial fibrillation

**M. Sgueglia** (Rome, I)

* Impact of cardiorespiratory fitness on atrial fibrillation burden   
  **B. Di Giacinto** (Rome, I)

Predisposing factors to ventricular proarrhythmia during antiarrhythmic therapy in normal heart  
**TBA**

Wednesday, November 30

**11:00-12:30**

# Multipoint Left Ventricle Pacing: clinical benefit or a gadget?

Chairs:  **M.G. Bongiorni** (Pisa, I)  
**J.J. Garcia** **Guerrero** (Badajoz, E)

* MPP: rationale and acute programming optimization

**TBA**

* MPP in real life: is always possible to use it?

**P.P. Delnoy** (Zwolle, NL)

* MPP and the challenge of the ischemic patients

**A. Vado** (Cuneo, I)

* MPP in special patients subgroups: non responders

**D. Gras** (Nantes, F)

* MPP in special patients subgroups: narrow QRS

**M. Gasparini** (Rozzano, I)

* MPP: long term follow up

**Z. Calovic** (Milan, I)

Wednesday, November 30

**11:00-12:30**

# 

# Quadripolar LV leads for CRT: a new standard

Chairs: **L. Santini** (Rome, I)  
**B. Thibault** (Montreal, F)

* Available quadripolar leads: features and differences  
  **C. D’Agostino** (Bari, I)
* Which patients may benefit more by a quadripolar LV lead?

**S. Po** (Oklahoma City-OK, USA)

* Vector selection and pacing configuration programming at implant: which methods and targets?  
  **G.B. Forleo** (Rome, I)
* Vector selection and pacing configuration programming at follow-up: which methods and targets?

**A. Rapacciuolo** (Naples, I)

* Quadripolar leads for CRT: clinical outcomes

**M. Roser** (Berlin, D)

* Quadripolar leads for CRT: do they reduce costs?

**G. Pastore** (Rovigo, I)

Wednesday, November 30

**11:00-12:30**

**channelopathies: state of the art**

Chairs: **C. Giustetto** (Turin, I)

**N. Takahashi** (Oita, JP)

* Future direction for research in improving diagnosis

**M. Gnecchi** (Pavia, I)

* Future direction for research in improving therapy

**D.L. Packer** (Rochester-MN, USA)

* Novel insights on SCD risk stratification

**A.S. Fak** (Istanbul, TR)

* New echocardiographic insights on channelopathies: is it always true that patients have a normal heart?

**A.I. Guaricci** (Foggia, I)

* Channelopathies and sport activity

**L. Crotti** (Pavia, I)

* Management of asymptomatic patients with inherited arrhythmic disorders

**G. Ciconte** (Catanzaro, I)

Wednesday, November 30

**11:00-12:30**

**THE ALL-IN-ONE SOLUTION FOR CARDIAC ARRHYTHMIAS MAPPING AND TREATMENT**

Chairs: **C. Pandozi** (Rome, I)   
**TBA**

* Clinical Benefits of the new Carto 3 Confidense Module in substrate ablation of Ventricular Tachycardia

**G. Senatore** (Ciriè-TO, I)

* New advances in the treatment of Atrial Fibrillation: why and how RF makes the difference in obtaining effective lesion formation?

**A. Dello Russo** (Milan, I)

* Paroxysmal Atrial Fibrillation: is the new Circular Mapping and Ablation Technology the answer?

**M. Grimaldi** (Acquaviva delle Fonti-BA, I)

* Carto 3 SmartTouch: the best-in-class Technology for an effective treatment of cardiac arrhythmias

**L. Calò** (Rome, I)

* Usefulness of Intracardiac Eco in reducing fluoroscopy during mapping and ablation in complex arrhythmias

**F. Lamberti** (Milan, I)

Wednesday, November 30

**11:00-12:30**

**AF ABLATION: innovative techniques and procedures**

Chairs: **P. Notarstefano** (Arezzo, I)  
**TBA**

* LAA isolation for long-standing persistent AF   
  **L. Di Biase** (Austin-TX, USA)
* [Benefits of multi electrode catheters for AF mapping and ablation](http://mail.elsevierhealth.com/cgi-bin23/DM/x/n4Up0IqcYL0INz0BTzZz0El)

**J. Seitz** (Marseille, F)

* Cooling vs heating: Lessons learned from imaging AF ablation patient

**N.F. Marrouche** (Salt Lake City, USA)

* High resolution 3D mapping system to localize critical isthmuses and foci

**M. Scaglione** (Asti, I)

* AF ablation: A Visually Guided Laser Balloon for pulmonary vein isolation

**TBA**

Wednesday, November 30

**12:30-14:00**

**“STATE OF THE ART” LECTURES**

Chairs: **F. Anselme** (Rouen, F)  
**A. Brandes** (Odense, DK)

* Genomics of atrial fibrillation

**S. Kääb** (Munich, D)

* Evidence - based safety and efficacy of Non-Vitamin K Anticoagulants in patients with atrial fibrillation

**TBA**

Wednesday, November 30

**12:30-14:00**

**DEBATES**

Chairs: **P. L. Danna** (Milan, I)  
**D. Mocini** (Rome, I)

* Occlusion of the left atrial appendage is preferable to anticoagulation to prevent stroke in atrial fibrillation patients
* PROS

**L.V. Boersma** (Nieuwegein, NL)

* CONS

**P. Sommer** (Leipzig, D)

* Should we continue to ablate the renal sympathetic nerves to treat hypertension?
* PROS

**TBA**

* CONS

**R. Hatala** (Bratislava, SK)

Wednesday, November 30

**12:30-14:00**

**DEBATES**

Chairs: **D. Pecora** (Brescia, I)  
**V.P. Vassilikos** (Thessaloniki, GR)

* Implanting CRT in the patient with RBBB is useless and potentially dangerous
* PROS

**TBA**

* CONS

**M. Gasparini** (Milan, I)

* All the CRT implant in AF patients should be completed by an AV node ablation
* PROS

**TBA**

* CONS

**S. Nardi** (Catel Volturno-CE, I)

Wednesday, November 30

**12:30-14:00**

**DEBATES**

Chairs: **S. Porcellini** (Milan, I)  
**TBA**

* Atrial flutter ablation should always be completed by an adjunctive AF ablation
* PROS

**TBA**

* CONS

**A. Natale** (Austin-TX, USA)

* Hybrid ablation surgical and endocavitary should be the first choice technique to treat persistent atrial fibrillation
* PROS

**C. Pandozi** (Rome, I)

* CONS

**J.C. Deharo** (Marseille, F)

Wednesday, November 30

**14:00-15:30**

**Cardiac resynchronization therapies: technical issues**

Chairs: **D. Gras** (Nantes, F)  
 **A. Proclemer** (Udine, I)

* RV apex vs RV high septum pacing: differences on biventricular hemodynamic function

**TBA**

* Quadripolar leads & best pacing vector selection  
  **S. Faerestrand** (Bergen, N)
* Active fixation endocardial leads for CRT

**G. Luzzi** (Bari, I)

* Quadripolar vs bipolar lead stimulation: clinical evidence

**M. Ziacchi** (Bologna, I)

* Is His-bundle pacing an alternative to CRT?

**F. Zanon** (Rovigo, I)

* Medium term results of LV endocardial pacing across intraventricular septum

**J.M. Morgan** (Southampton, UK)

Wednesday, November 30

**14:00-15:30**

**EURO-JAPAN ARRHYTHMIA FORUM (EJAF)**

**Session I**

**CRT: alternative approaches to left ventricular pacing**

Chairs: **Y. Nakazato** (Tokyo, JP)  
**M. Santini** (Rome, I)

* When should we “Think different”: prior failed CS lead implantation or Non responders?  
  **TBA**
* Endocardial vs Epicardial LV pacing: what’s the truth?  
  **H. Hayashi** (Tokyo, JP)
* Sub-xyphoid Pericardial approach for Left ventricle epicardial pacing  
  **K. Imai** (Hiroshima, JP)
* Managing electrical storm in CRT-D patients   
  **T. Kurita**（Osaka, JP）
* New Technology Discussion.：Leadless LV pacing. Japanese experience  
  **K. Aonuma** (Tsukuba, JP)

Wednesday, November 30

**14:00-15:30**

**FORUM ON REMOTE CONTINUOUS MONITORING**

**Session 1**

**ILR: Transition from diagnosis to therapy**

Chairs: **D.G. Benditt** (Minneapolis-MN, USA)

**M. Brignole** (Lavagna-GE, I)

* 15 years of ILR: what did we learn?

**R.S. Sheldon** (Calgary-AB, CDN)

* ILR follow up management

**I. Diemberger** (Bologna, I)

* Neuromediated syncope: to implant or not to implant

**S. Bianchi** (Rome, I)

* ILR: brightening dark zones

**S. Strano** (Rome, I)

* ILR in athletes

**F. Giada** (Mestre-VE, I)

* ILR: health technology assessment

**P. Pezawas** (Vienna, A)

Wednesday, November 30

**14:00-15:30**

**ATRIAL FIBRILLATION THERAPY IN THE ER**

Chairs: **G. Inama** (Crema, I)

**O. Oseroff** (Buenos Aires, RA)

* When an echocardiogram may be avoided before starting to treat an atrial fibrillation patient in the ER?

**TBA**

* How to select the first option drug to stop atrial fibrillation

**A. Jazra** (Beirut, RL)

* Transesophageal echo is always necessary before electrical cardioversion

**C. Cianfrocca** (Rome, I)

* Efficacy of flecainide prolonged release in Atrial fibrillation prevention and treatment: data from the real world

**G. Boriani** (Modena, I)

* Hybrid therapy: pacing and antiarrhythmic drugs to prevent AF recurrences

**M. Santomauro** (Naples, I)

Wednesday, November 30

**14:00-15:30**

**S-ICD: the dark side of the moon**

Chairs: **A. Grace** (Cambridge, UK)  
**TBA**

* Missing ATP

**P. Francia** (Rome, I)

* Why still Defibrillation threshold test is mandatory?

**TBA**

* Managing of incoming brady or CRT indications

**V. Probst** (Nantes, F)

* Patient screening and inappropriate shocks

**P. De Filippo** (Bergamo, I)

* Is AF a controindication?

**TBA**

* S-ICD: too expensive?

**L. Tomasi** (Verona, I)

Wednesday, November 30

**14:00-15:30**

**upgrading and downgrading of electrical therapy: when, why, fruitful, dangerous?**

Chairs: **A. Quesada** (Valencia, E)  
**M. Toscano** (Colleferro-RM, I)

* Upgrading from conventional pacing to CRT-P

**A. Hamaad** (Walsall, UK)

* Upgrading from single to double chamber ICD for primary prevention of sudden death

**C.D. Di Candia** (Bari, I*)*

* Upgrading from dual chamber ICD to CRT-D

**A. D’Onofrio** (Naples, I)

* Downgrading to VVI or DDD pacing after explantation of an infected single or dual chamber ICD without shocks during the follow-up

**J. Bytesnik** (Prague, CZ)

* Downgrading from an explanted, infected double, triple chamber ICD to subcutaneous ICD

**A. Salvati** (Rome, I)

* Upgrading of DDD pacing to dual chamber defibrillator by subcutaneous ICD adjunctive implantation

**G. Tola** (Cagliari, I)

Wednesday, November 30

**14:00-15:30**

[**Paroxysmal atrial fibrillation ablation: Where and how much to ablate?**](http://mail.elsevierhealth.com/cgi-bin23/DM/x/n4y20IqcYL0INz0BUPp30Ep)

Chairs: **T. Hanke** (Luebeck, D)  
**A. Nogami** (Tsukuba, JP)

* Stepwise ablation or pulmonary vein isolation in patients with paroxysmal atrial fibrillation: which is the best option?

[**M. Faustino**](javascript:void(0);) (Pescara, I)

* Importance of non-pulmonary vein foci in catheter ablation for  
  paroxysmal atrial fibrillation   
  **K. Uno** (Tokyo, JP)

* A minimal or maximal ablation strategy for paroxysmal atrial fibrillation, which is the best choice?

**T. Gaspar** (Dresden, D)

* When to add Autonomic denervation to pulmonary vein isolation for paroxysmal atrial fibrillation?   
  **M. Fantinel** (Feltre-BL, I)
* When should we give up from ablation for AF?

**F. Turreni**  (Rome, I)

* Different outcomes according to individually tailored strategies for AF ablation

**A. Berkowitsch** (Bad Nauheim, D)

Wednesday, November 30

**15:30-17:00**

**ARRHythmic issues and DEVICE therapy in heart failure with preserved ejection fraction**

Chairs: **G. Ansalone** (Rome, I)

**Y. Nakazato** (Tokyo, JP)

* SCD epidemiology and arrhythmic risk stratification

**G. Barbato** (Bologna, I)

* AF incidence and management

**M. Martinek** (Innsbruck, A)

* Pulmonary artery pressure monitoring

**M.D. Carlson** (Sylmar-CA, USA)

* Cardiac contractility modulation

**M. Borggrefe** (Mannheim, D)

* Baroreflex Activation Therapy

**E. Caradonna** (Campobasso, I)

* Spinal cord stimulation

**H.F. Tse** (Hong Kong, Republic of China)

Wednesday, November 30

**15:30-17:00**

**EURO-JAPAN ARRHYTHMIA FORUM (EJAF)**

**Session II**

**Heart failure: current & future ways to manage HF patients**

Chairs: **T. Nitta (**Tokyo, JP)  
**TBA**

* Strategies on building a HF clinic   
  **TBA**
* Current device-based algorithms to manage HF patients   
  **T. Nakai** (Tokyo, JP)
* Management of HF patients with CRT-Ds – is it effective?  
  **A. Oto** (Ankara, TR)
* Development or deterioration of Heart Failure in AF patients  
  **R. Kato** (Saitama, JP)
* New Technology Forum: An introduction to pulmonary artery pressure monitoring with CardioMEMS  
  **TBA**

Wednesday, November 30

**15:30-17:00**

**IMAGING to improve diagnosis and treatment in cardiac aRrhythmias**

Chairs: **J. Brachmann** (Coburg, D)  
**M.T. Stewart** (Mounds View-MN, USA)

* MRI myocardial fibrosis quantification to predict CRT response

**C.A. Rinaldi** (London, UK)

* MR imaging to understand CRT failure

**M. Bertini** (Ferrara, I)

* MRI to predict AF ablation outcomes

**J.B. Le Polain de Waroux** (Brussels, B)

* Cine MR imaging to quantify inter-appendicular dyssynchrony in AF patients

**TBA**

* Superiority of MRI to transthoracic ECHO in the sudden death risk stratification

**TBA**

* Usefulness of positron emission tomography in lead endocarditis

**L. Inama** (Brescia, I)

Wednesday, November 30

**15:30-17:00**

**long term follow-UP of crt trials**

Chairs: **J.O. Schwab** (Bonn, D)  
**TBA**

* Long Term survival and quality of life   
  **F. Briand** (Besançon, F)
* The role of lead location and outcome

**N. Krasniqi** (Wetzikon, CH)

* Outcomes in PMK dependent patients upgraded from conventional PMK

to CRT-D

**D. Potenza** (S. Giovanni Rotondo-FG, I)

* Magnitude of response to CRT according to Gender and QRS duration   
  **V. Zacà** (Siena, I)
* Weekly automatic CRT optimization in clinical practice

**G. Covino** (Naples, I)

* Effects on health care resource utilization and costs of enhanced pacing modalities

**G. Ciaramitaro** (Palermo, I)

Wednesday, November 30

**15:30-17:00**

**S-ICD: the bright side of the moon**

Chairs: **G.L. Botto** (Como, I)

**P.D. Lambiase** (London, UK)

* Pediatric patients

**R. Remoli** (Rome, I)

* After lead extractions

**TBA**

* Primary prevention? Secondary prevention? Both?

**A. Vado** (Cuneo, I)

* S-ICD and leadless pacemaker: the “perfect system”

**M.G. Bongiorni** (Pisa, I)

* S-ICD: patients’ acceptance

**E. De Ruvo** (Rome, I)

* S-ICD: Health Technology assessment

**A. Droghetti** (Mantova, I)

Wednesday, November 30

**15:30-17:00**

**NEUROMODULATION THERAPY IN heart FAILURE: IS THERE STILL HOPE?**

Chairs: **M. Santini** (Rome, I)

**M. Senni** (Bergamo, I)

* Neuromodulation: A relevant approach for HF?  
   **E. Vanoli** (Pavia, I)
* Vagal Stimulation: Where are we?  
   **G. De Ferrari** (Turin, I)
* Baroreflex Activation Therapy: More than a promise  
  **E.G. Gronda** (Sesto S. Giovanni-MI, I)

**Q&A – Chairpersons & Audience**

Wednesday, November 30

**15:30-17:00**

# 

# New predictors of response to cardiac resynchronization therapy

Chairs: **G. Altamura** (Rome, I)  
 **C.W. Israel** (Bielefeld, D)

* QRs duration and morphology remain the most powerful predictors of CRT positive response

**D. Grieco** (Rome, I)

* Worsening of clinical outcome may be predicted by increase of QRS duration during CRT follow-up?

**L. De Luca** (Rome, I)

* CRT: the role of left atrium function   
  **M. Viscusi** (Caserta, I)
* Acute hemodynamic evaluation: is it obsolete?

**TBA**

* The role of MRI  
  **A. Hernandez-Madrid** (Madrid, E)
* CRT non responders: manageable? Unavoidable?

**A. Maass** (Groningen, NL)

Thursday, December 1

**9:00-10:30**

**The PAIN FREE ICD: a reality?**

Chairs: **M. Landolina** (Crema, I)  
**F. Leyva** (Birmingham, UK)

* Multi-algorithms’ devices: are they effective?

**J.O. Schwab** (Bonn, D)

* Efficacy of Right ventricular and left ventricular ATP

**M. Zardini** (Parma, I)

* Optimal programming for a shockless therapy?

**E.C.L. Pisanò** (Lecce, I)

* Patient outcome deterioration after multiple ICD shocks

**R. Rordorf** (Pavia, I)

* Psychological damage by frequent ICD shocks

**TBA**

* The electrical storm due to lead fracture: how to manage?

**G. Zucchelli** (Pisa, I)

Thursday, December 1

**9:00-10:30**

**ICD: TEchnical issues**

Chairs: **H. Abe** (Kitakyushu, JP)   
**R. Sutton** (Monte Carlo, Monaco)

* Single and dual coil defibrillation leads outcomes   
  **L.R. Scott** (Phoenix-AZ, USA)
* Do we still need testing of the defibrillation threshold?   
  **M. Takagi** (Osaka, JP)
* Reduction of shock burden in CRT-D with quadripolar leads   
  **TBA**
* Is Triple site ventricular pacing superior to conventional biventricular pacing?   
  **Y. Sekiguchi** (Tsukuba, JP)
* Optimization of device setting to increase its longevity  
  **G.B. Magenta** (Milan, I)
* ICD remote control to reduce inappropriate shocks   
  **TBA**

Thursday, December 1

**9:00-10:30**

**NON INVASIVE IMAGING TO STRATIFY THE RISK OF CARDIAC SUDDEN DEATH**

Chairs: **M. Khoury** (Beirut, RL)

**R. Luise** (L’Aquila, I)

* Re-evaluating the role of surface ecg

**C.E.P. Brough** (Liverpool, UK)

* Continuous ECG monitoring

**E.T. Locati** (Milan, I)

* Echocardiographic anatomical markers

**S. Ficili** (Rome, I)

* Echocardiographic functional markers

**A. Auriti** (Rome, I)

* Nuclear cardiac imaging

**TBA**

* Cardiac MRI

**C. Bucciarelli Ducci** (Bristol, UK)

Thursday, December 1

**9:00-10:30**

**improving the success rate of ventricular tachycardia ablation**

Chairs: **P. Adragao** (Carnaxide, P)

**G. Senatore** (Ciriè-TO, I)

* Correlation between  cardiac innervation and ventricular arrhythmias substrate: clinical impact on ablation procedure  
  **F. Menichetti** (Pisa, I)

* Intracardiac imaging to improve VT ablation success rate  
  **C. Carbucicchio** (Milan, I)
* New mapping systems for near zero Xray successful VY ablation  
  **M. Moltrasio** (Milan, I)

* Verapamil – sensitive right and left ventricular tachycardia ablation: which technique? Which success rate?  
  **B. Dinov** (Leipzig, D)
* Increase of success rate and decrease in complications of VT ablation using Contact-Force Catheters   
  **TBA**
* VT ablation in right and left ventricular arrhythmogenic dysplasia  
  **N. Trevisi** (Milan, I)

Thursday, December 1

**9:00-10:30**

**ATRIAL FIBRILLATION CLINICAL FOLLOW-UP AND MANAGEMENT**

Chairs: **F.** **Bellocci** (Rome, I)  
**Y. Kobayashi** (Tokyo, JP)

* Can we predict and prevent new onset atrial fibrillation?

**D. Bastian** (Nuremberg, D)

* Factors predicting the progression from paroxysmal to persistent atrial fibrillation

**D. Catanzariti** (Rovereto-TN, I)

* Does atrial fibrillation burden identify risk of adverse cardiovascular events

**J.N. Catanzaro** (Jacksonville-FL, USA)

* Stroke and heart failure survival after atrial fibrillation

**A. Borrelli** (Rome, I)

* Safety to discontinue anticoagulation after a successful ablation

**V. Ribatti** (Rome, I)

Thursday, December 1

**9:00-10:30**

**re-evaluating crt-p pacing modality**

Chairs: **R. Piotrowicz** (Warsaw, P)  
**F. Solimene** (Mercogliano-AV, I)

* Long – term results of CRT-P in Heart Failure   
  **R.A. Kaba** (Chertsey, UK)
* Should we select CRT-P as first option therapy for patients with complete AV block and reduced EF?

**A. Blandino** (Vercelli, I)

* When to upgrade from DDD to CRT-P pacing modality?

**M. Giaccardi** (Florence, I)

* When to upgrade from VVI to CRT-P pacing modality in patients with atrial fibrillation?

**M. Ziacchi** (Bologna, I)

* Is left ventricular pacing alone acceptable in patients with complete LBBB?

**TBA**

* CRT in non LBBB patients?

**V. Ducceschi** (Vallo Lucania-SA, I)

Thursday, December 1

**9:00-10:30**

**LONG term outcome after af ablation**

Chairs: **J.L. Merino** (Madrid, E)   
**A.S. Montenero** (Sesto S. Giovanni-MI, I)

* The impact of age on long term outcome after AF ablation

**L. Ottaviano** (Milan, I)

* Left atrial shape predicts recurrences post AF ablation

**Q. Parisi** (Campobasso, I)

* Recurrences of AF post ablation in clinical practice: data from national registries

**S. Ikeguchi** (Moriyama City, JP)

* Impact of the extent of atrial low voltage on post-ablation AF recurrences

**G. Bisignani** (Catrovillari-CS, I)

* Impact of different atrial fibrillation foci on post ablation long term outcomes

**L. Macle** (Montreal, CDN)

* Impact of AF ablation on quality and quantity of life

**R. Mantovan** (Cesena-FC, I)

Thursday, December 1  
**11:00-12:30**

**Atrial arrhythmias management between diagnostics and therapy**

Chairs: **G. Maglia** (Catanzaro, I)  
**R. Willems** (Leuven, B)

* Is early detection of AF through Home Monitoring has a role in thromboembolic risk reduction?  
   **D. Vaccari** (Montebelluna-TV, I)

* AF ablation: new mapping systems or other strategies?  
  **TBD**
* Practical management of atrial arrhythmias in ICD population: the DX experience  
  **C. Budano** (Turin, I)
* Prevention of cryptogenetic stroke with insertable cardiac monitor  
  **L. Santini** (Rome, I)
* Outcome monitoring of AF ablation through insertable cardiac monitor  
  **G. Senatore** (Ciriè-TO, I)
* The role of heart rate modulation in the tachy patient pool  
  **C.C. De Cock** (Amsterdam, NL)

Thursday, December 1

**11:00-12:30**

**FOCUS ON ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA**

Chairs: **K. Hirao** (Tokyo, JP)  
**L. Leoni** (Padua, I)

* Anatomical and pathological review of ARVD  
  **M. Galeazzi** (Rome, I)
* Novel insights ECG abnormalities in ARVD  
  **N. Nishii** (Okayama, JP)
* Is Phenotypic expression useful to stratify high risk patients of SCD?  
  **M. Horie** (Shiga, JP)
* Electrophysiologic substrate and risk stratification  
  **V. Schirripa** (Rome, I)
* Prognostic value of ablation and ICD therapy  
  **K. Satomi** (Tokyo, JP)
* Clinical perspectives in ARVD: Japanese experience  
  **T. Noda** (Osaka, JP)

Thursday, December 1

**11:00-12:30**

**Progress in HF management**

* HF and CRT optimization (20 m)
* Co-Chairman and Discussant (10 m)
* HF and Sleep Apnea (20 m)
* Co-Chairman and Discussant (10 m)
* HF and neuromodulation (20 m)
* Co-Chairman and Discussant (10 m)

Thursday, December 1

**11:00-12:30**

**NEW TECHNOLOGIES FOR A BETTER PATIENT OUTCOME**

Chairs: **A. Campana** (Salerno, I)  
**TBA**

* The leadless pacemaker single, double, triple chamber?

**F.A. Bracke** (Eindhoven, NL)

* “One-shot technique”: a first chance therapy for atrial fibrillation ablation?

**N. Bottoni** (Reggio Emilia, I)

* The quadripolar lead and multi-vectorial pacing to reduce CRT non responders?

**G.B. Forleo** (Rome, I)

* Update in shock reduction strategies

**P. Scipione** (Ancona, I)

* Closed loop stimulation and sleep apnea: rationale and results

**G. Nigro** (Naples, I)

* ICD extended longevity: clinical and economical impact

**E. De Ruvo** (Rome, I)

Thursday, December 1

**11:00-12:30**

**THE NEW FRONTIERS OF ATRIAL FIBRILLATION ABLATION**

Chairs: **E. Crystal** (Toronto-ON, CDN)  
**K. Yamashiro** (Takatsuki City, JP)

* New tools for AF ablation

**A. Di Cori** (Pisa, I)

* Rotor identification techniques

**L. Vitali-Serdoz** (Nuremberg, D)

* How high resolution signal could improve patients treatment and outcome

**A. De Simone** (Maddaloni-CE, I)

* Robotic technology to facilitate atrial fibrillation ablation

**G. Vicedomini** (S. Donato Milanese-MI, I)

* The hybrid approach, endocardial and epicardial ablation

**A. Bulava** (České Budějovice, CZ)

* Zero X-ray for EF ablation

**R. Cataldo** (Scottsdale-AZ, USA)

Thursday, December 1

**11:00-12:30**

**IMPACT OF AF THERAPEUTICAL STRATEGIES ON MORTALITY: positive? negative? neutral?**

Chairs: **O. Berenfeld** (Ann Arbor-MI, USA)  
**K. Okishige** (Yokohama, JP)

* Antiarrhythmic drugs for AF and mortality

**M. Disertori** (Trento, I)

* Rate control drugs for AF and mortality

**G. Rodriguez Diez** (Santa Fe-NM, USA)

* Antithrombotic drugs for AF and mortality

**F. Andreotti** (Rome, I)

* Up-stream therapy for AF and mortality

**F. Guerra** (Ancona, I)

* Non pharmacological treatment of AF and mortality

**TBA**

* “Put the points above in order of priority…”

**A. Capucci** (Ancona, I)

Thursday, December 1

**11:00-12:30**

### MODERN cardiology: HOW TO MANAGE PEDIATRIC PATIENTS

Chairs: **J.** **Janousek** (Prague, CZ)

**J.A. Salerno Uriarte** (Varese, I)

* Physiopathology of pediatric arrhythmias

**TBA**

* How to diagnose pediatric arrhythmias

**TBA**

* How to manage WPW pediatric patient

**F. Drago** (Rome, I)

* How to manage ablation in pediatric patients

**G. Brugada** (Barcelona, E)

* How to manage implanted device in pediatric patients

**P. De Filippo** (Bergamo, I)

* How to manage interatrial defect in pediatric patients

**G. Butera** (Milan, I)

Thursday, December 1

**12:30-14:00**

**“STATE OF THE ART” LECTURES**

Chairs: **F. Crea** (Rome, I)  
**TBA**

* Vagal rescue optimization in advanced HF

**A. Maass** (Groningen, NL)

* Role of renal denervation in advanced HF

**TBA**

Thursday, December 1

**12:30-14:00**

**DEBATES**

Chairs: **M. Bocchiardo** (Pietra Ligure-SV, I)  
**TBA**

* Should all new implanted devices be MRI conditional?
* PROS

**A. Roguin** (Haifa, IL)

* CONS

**G. Zucchelli** (Pisa, I)

* Should all CIED patients with bacteremia undergo lead exctraction?
* PROS

**M. Russo** (Rome, I)

* CONS

**C.T. Starck** (Berlin, D)

Thursday, December 1

**12:30-14:00**

**DEBATES**

Chairs: **J.W.E. Jarman** (London, UK)  
**TBA**

* Primary preventions ICD at end of battery life should not be replaced in patients with recovered LV systolic function
* PROS

**TBA**

* CONS

**A. Sagone** (Milan, I)

* Subcutaneous ICD should be preferred for primary preventions of sudden death to the transvenous system
* PROS

**TBA**

* CONS

**A. Arenal-Maiz** (Madrid, E)

Thursday, December 1

**12:30-14:00**

**DEBATES**

Chairs: **G. Bencsik** (Szeged, H)

**S. Paraskevaidis** (Thessaloniki, GR)

* Ablation of persistent atrial fibrillation in Heart Failure patients should be avoided

* PROS

**R. Cappato** (Bergamo, I)

* CONS  
  **TBA**
* Performing MRI scan in patients wearing not MRI conditional PMK or ICDs
* PROS  
  **C. Schukro** (Wien, A)
* CONS  
  **J.J. Blanc** (Brest, F)

Thursday, December 1  
**14:00-15:30**

**CRT and beyond**

Chairs:  **A. Curnis** (Brescia, I)  
**M. Oliveira** (Lisbon, P)

* Why do women better respond to CRT? The BIOWOMEN rational, design and expectation  
  **M.J. Sancho–Tello** (Valencia, E)
* Replacement strategy in CRT responders: the BIOCONTINUE Study   
  **D. Gras** (Nantes, F)
* Home Monitoring and CRT: can it improve HF patient response?   
  **G. Mascioli** (Bergamo, I)
* Does one LV lead fit all needs?  
  **G. Rovaris** (Monza, I)
* Has transthoracic impedance a role as early marker for CRT response?   
  **S. Iacopino** (Bari, I)
* Multipolar pacing: evidences as of today and open questions   
  **P.S. Cunha** (Lisbon, P)

Thursday, December 1

**14:00-15:30**

**INCOMING CHALLENGES FOR REMOTE MONITORING OF IMPLANTABLE DEVICES**

Chairs: **R.P. Ricci** (Rome, I)  
**TBA**

* How to [integrate more and more remote monitoring of cardiac implantable electronic devices into daily clinical practice](http://click.info.escardio.org/?qs=5e9b1cd002850be3ae19a048d5182ad254e9d2470150370a083da4bc856ff7c5): a cultural or an economic problem?

**M.S. Baccillieri** (Camposampiero-PD, I)

* The hub and spoke model to facilitate the implementation of remote monitoring both in hospital and out of hospital

**G. Giannola** (Cefalù-PA, I)

* The Relationship Between Level of Adherence to Remote Monitoring and Survival in Pacemaker and Defibrillator Patients   
  **C.W. Israel** (Bielefeld, D)
* Are we ready for a more patient centric health care?

**G. Augello** (Milan, I)

* Diagnostic data management tools: the real impact on clinical practice

**L. Calò** (Rome, I)

* Remote Monitoring: A potential source of legal troubles especially with respect to privacy issue?

**M. Chudzik** (Lódź, PL)

Thursday, December 1

**14:00-15:30**

**THE SUBCUTANEOUS ICD: CLINICAL IMPLICATIONS AFTER 4 YEAR FOLLOW-UP**

Chairs: **F. Gadler** (Stockholm, S)  
**J. Sperzel** (Bad Nauheim, D)

* The subcutaneous ICD implant rate worldwide: is it according to what expected?

**F. Caravati** (Varese, I)

* Sensitivity and specificity of the subcutaneous pre-implant screening tool

**P.P. Delnoy** (Zwolle, NL)

* Subcutaneous ICD inappropriate shocks compared to the conventional ICD

**M. Luzi** (Ancona, I)

* The hybrid approach: subcutaneous ICD and leadless pacemakers

**W. Jung** (Villingen-Schwenningen, D)

* Subcutaneous ICD in hypertrophic cardiomyopathy

**F. Cecchi** (Florence, I)

* Can subcutaneous ICD reduce ICD implant complications in dialytic patients?

**E.C.L. Pisanò** (Lecce, I)

Thursday, December 1

**14:00-15:30**

**AF ABLATION: clinical issues**

Chairs: **K.H. Kuck** (Hamburg, D)

**C. Pratola** (Ferrara, I)

* Demographic differences in patients undergoing atrial fibrillation ablation  
  **M. Rebecchi** (Rome, I)
* [May pretreatment with angiotensin-converting enzyme inhibitors improve ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction?](http://mail.elsevierhealth.com/cgi-bin23/DM/x/n4y20IqcYL0INz0BUPqA0E5)

**L. Di Biase** (Austin-TX, USA)

* Are all AF patients the same?: AF ablation in patients with hypertrophic cardiomyopathy

**G. Maglia** (Catanzaro, I)

* Impact of hyperthyroidism on long-term outcome of catheter ablation of drug-refractory atrial fibrillation

**G. Carreras** (Terni, I)

* Could we identify a list of anatomical and functional parameters to predict AF recurrences post AF ablation?  
  **TBA**
* Antiarrhythmic drugs therapy after AF cathether ablation: how long should we keep on?   
  **H. Yokoshiki** (Sapporo, JP)

Thursday, December 1

**14:00-15:30**

**REDUCING ARRHYTHMIA RECURRENCES AFTER PAROXYSMAL ATRIAL FIBRILLATION ABLATION**

Chairs: **A. Natale** (Austin-TX, USA)  
**D.L. Packer** (Rochester-MN, USA)

* Early catheter ablation as first line treatment for PAF: less recurrences?

**M. Giaccardi** (Florence, I)

* The importance of higher contact force values to determine the outcome of PAF ablation

**A. Bonso** (Feltre-BL, I)

* Better outcome of PAF ablation with the new cryoballoon catheters

**C. Straube** (Munich, D)

* Pulmonary vein trigger and atrial flutter: which is the link?

**P. Santangeli** (Philadelphia-PA, USA)

* Atrial fibrillation frequent occurrances after supraventricular arrhythmia ablation: do we need a prophylactic treatment?

**TBA**

* Recurrence after “long term success” in PAF ablation: the same or a new arrhythmia?

**M. Brunelli** (Magdeburg, D)

Thursday, December 1

**15:30-17:00**

**Bad things happen to those who wait too long**

Chairs: **C. Wolpert** (Ludwigsburg, D)

**TBA**

* SCD in long interdialityc period

**S. Castelletti** (London, UK)

* ICD timing after cardiac revascularization

**G. Dell’Era** (Novara, I)

* NOAC start in silent AF detected by device

**W. Jung** (Villingen-Schwenningen, D)

* PMK after syncope in bifascicular block

**F. Giada** (Mestre-VE, I)

* Lead extraction after pocket erosion

**R. De Lucia** (Pisa, I)

* AVN ablation in CRT patients with AF with low biventricular pacing rate

**D.L. Lustgarten** (Burlington-VT, USA)

Thursday, December 1

**15:30-17:00**

# Improving outcomes in patients with advanced heart failure

Chairs: **G. Vergara** (Rovereto-TN, I)  
**TBA**

* Adding baromodulation to CRT-D

**TBA**

* CRT-D optimization with multipoint pacing

**D. Potenza** (S. Giovanni Rotondo-FG, I)

* CRT management in patients with atrial fibrillation

**G. Giannola** (Cefalù-PA, I)

* Benefit of renal denervation in Heart Failure treatment

**K. Kaczmarek** (Lodz, PL)

* The role of eplerenone in patients with systolic heart failure   
  **M. Scherillo** (Benevento, I)
* The untreatable heart failure: LVAD or new surgical LV restructuring?  
  **F. Musumeci** (Rome, I)

Thursday, December 1

**15:30-17:00**

**Update on Leads Extraction**

Chairs: **M.G. Bongiorni** (Pisa, I)  
**M. Chauvin** (Strasbourg, F)

* What should be foreseen before a lead extraction: materials, facility, back-up

**L. Bontempi** (Brescia, I)

* Extraction of superfluous device leads: Pros and Cons   
  **F. Franceschi** (Marseille, F)
* Lessons from Sprint Fidelis and Riata leads extraction  
  **E. Cronin** (Hartford-CT, USA)
* When and how to reimplant a device in a PMK dependent patient

**P. Pieragnoli** (Florence, I)

* The surgical back-up: should it be mandatory?

**S. Benussi** (Milan, I)

* Can an infected leadless pacemaker be more dangerous than an infected lead?

**A. Maciag** (Warsaw, PL)

Thursday, December 1

**15:30-17:00**

**AF ABLATION: Technical Issues**

Chairs: **B. Köktürk** (Koln, D)  
**T. Yamane** (Tokyo, JP)

* The optimal anticoagulation strategy for atrial fibrillation ablation   
  **G. Bencardino** (Rome, I)
* Feasibility and efficacy of AF ablation in patients with left atrial appendage closure devices   
  **TBA**
* Increasing catheter contact force improves AF ablation outcome

**TBA**

* New [spatiotemporal mapping to improve outcome in persistent atrial fibrillation ablation](http://mail.elsevierhealth.com/cgi-bin23/DM/x/n4y20IqcYL0INz0BUPp60Es)

**TBA**

* Is the Orion mini-basket catheter a “small or a mega star” in the sky of AF ablation?

**R. Weiss** (Columbus-OH, USA)

* The era of “0 X-ray”: did we finally reach it?

**M. Anselmino** (Turin, I)

Thursday, December 1

**15:30-17:00**

**How NOAC changed Ep’s behaviour**

Chairs: **F. Colivicchi** (Rome, I)

**TBA**

* NOAC and Electrical Cardioversion

**S.A. Di Fusco** (Rome, I)

* NOAC and EP procedures

**TBA**

* NOAC and PMK and ICD implantation

**D. Ricciardi** (Rome, I)

* NOAC and LEADs extractions

**TBA**

* NOAC vs LAA occlusion

**TBA**

* NOAC antagonists

**M. Lettino** (Milan, I)

Thursday, December 1

**15:30-17:00**

**FORUM ON REMOTE CONTINUOUS MONITORING**

**Session III**

**ILR to guide and control therapy**

Chairs: **A. Raviele** (Mestre-VE, I)

**E.G. Vester** (Dusseldorf, D)

* ILR to start or to stop anticoagulation in atrial fibrillation patients

**E. Vanoli** (Pavia, I)

* ILR in atrioventricular and intraventricular conduction disturbances

**M. Tomaino** (Bolzano, I)

* ILR in post-MI patients with reduced EF

**I. Can** (Ankara, TR)

* ILR after VT ablation  
  **TBA**
* ILR in cardiomyopathies

**V. Romano** (Rome, I)

ILR after TAVI  
**O.V. Sapelnikov** (Moscow, Russian Federation)

Thursday, December 1

**15:30-17:00**

**MRI CONDITIONAL DEVICES: A NEW SCENARY**

Chairs: **F. Bokhari** (Jeddah, SA)  
**F. Mascia** (Caserta, I)

* MRI conditional devices: clinical evidences

**F. Melandri** (Sassuolo-MO, I)

* Upgrading or replacement of conventional systems: how to manage the MRI issue

**J. Senges** (Heidelberg, D)

* Labeling leads MRI-conditional: better a newly designed MRI lead or a tested backward compatibility of existing leads?

**B. Zrenner** (Munich, D)

* [MRI scanning in patients with MRI conditional devices: real life data](http://www.heartrhythmjournal.com/article/S1547-5271%2814%2901553-7/abstract)

**F. Borrello** (Reggio Calabria, I)

* MRI scan of patients with conventional not MRI conditional devices

**M.A. Rozner** (Houston-TX, USA)

* Legal and organizational issues for MRI scanning of CIEDs

**S. Rossi** (Saronno-VA, I)

Friday, December 2

**9:00-10:30**

**the transcatheter pacing systemS**

Chairs: **L.V. Boersma** (Nieuwegein, NL)  
**C. Tondo** (Milan, I)

* The need for a transcatheter pacing system

**S. Favale** (Bari, I)

* Technologies and implantation technique

**A. Curnis** (Brescia, I)

* TPS positioning in peculiar anatomies

**C. Pepper** (Leeds, UK)

* Clinical results

**M.G. Bongiorni** (Pisa, I)

* TPS and other implanted devices

**P. Neuzil** (Prague, CZ)

* What patients benefit the most?

**TBA**

Friday, December 2

**9:00-10:30**

**ROLE OF MAGNETIC RESONANCE IMAGING IN CARDIAC ARRHYTHMIAS DIAGNOSIS AND MANAGEMENT**

Chairs: **A.S. Al-Khadra** (Riyadh, SA)

**N. El Sherif** (New York-NY, USA)

* Cardiac MRI to quantify left atrial fibrosis in atrial fibrillation patients

**N.F. Marrouche** (Salt Lake City, USA)

* Cardiac MRI in inherited arrhythmogenic cardiomyopathies  
  **TBA**
* Cardiac MRI in hypertrophic cardiomyopathies

**N. Ajmone Marsan** (Leiden, D)

* Usefulness of cardiac MRI myocardial tissue characterization to predict ventricular arrhythmias in ischemic patients

**W.R. Bauer** (Wuerzburg, D)

* Cardiac MRI to stratify patients with primary cardiomyopathy candidates to ICD implant

**R. Zbinden** (Zurich, CH)

* MRI evaluating of left ventricular scar burden to guide CRT

**J.M. Behar** (Hertford, UK)

Friday, December 2

**9:00-10:30**

# 

**CIEDs: lesSons from long term registries and database**

Chairs: **L. Santini** (Rome, I)  
**TBA**

* Leadless pacemaker: where we are?

**L. Segreti** (Pisa, I)

* ICDs in clinical practice: when single chamber, dual chamber or single chamber with atrial sensing?

**P. Scipione** (Ancona, I)

* Implanting troubles and troubleshootings   
  **A. Proclemer** (Udine, I)
* Home monitoring and logistic model after 15 years from its introduction: what have we learned

**G. Zanotto** (Legnago-VR, I)

* The Future of CIEDs remote monitoring: automatic? Bidirectional?  
  **R.P. Ricci** (Rome, I)

|  |
| --- |
|  |

Friday, December 2

**9:00-10:30**

**Infected cardiac-implantable electronic devices: prevention, diagnosis, and treatment**

Chairs: **J. Clementy** (Bordeaux, F)  
**M. Zoni Berisso** (Genoa, I)

* Late device infections: relationship with the complexity of procedures  
  **P. Mazzone** (Milan, I)
* Guidelines for early and late prevention of cardiac implantable electronic device infections

**TBA**

* [Antibacterial 'Pouch' is it cost-effective?](http://click.mail.medscape.com/?qs=a4d21ca41fb59b39c95e808cc7ae7d8d051e7f0ff9719cfac4354da532b0fcdcfdf4a944962e49ab)

**P. Diotallevi** (Alessandria, I)

* Wearable cardioverter-defibrillator after removal of an infected ICD system: may be a solution?   
  **TBA**
* Pocket erosion: is lead extraction mandatory?

**C. Kennergren** (Goteborg, S)

* [Device system infections: medico-legal](http://click.info.escardio.org/?qs=ac3c3aa2efddfb4b1b5189df822d19eb82d59e7024466a1860345e4e90b23476) issues  
  **C. Riganti** (Naples, I)

Friday, December 2

**9:00-10:30**

**FORUM ON REMOTE CONTINUOUS MONITORING**

**Session IV**

**ILR in pediatric patients**

Chairs: **L. Binner** (Ulm, D)

**TBA**

* In congenital complete AV block

**K. Dagriri** (Riyadh, SA)

* In patients with palpitations

**L. Gianfranchi** (Ferrara, I)

* In patients fainting and with negative examination

**TBA**

* In GUCH patients

**V.E. Santobuono** (Bari, I)

* ILR to replace SEF in children

**M. Strieper** (Atlanta-GA, USA)

* ILR in children with channelopathies

**G.F. Van Hare** (St. Louis-MI, USA)

Friday, December 2

**9:00-10:30**

**ELETTROMAGNETIC INTERFERENCES AND CARDIAC IMPLANTABLE DEVICES**

Chairs:  **P. Merkely** (Budapest, H)  
**M. Zecchin** (Trieste, I)

* Intra-Hospital EMI sources but MRI

**R. Calvanese** (Bologna, I)

* EMI burden in daily life: which environmental waves should we beware?

**F. Censi** (Rome, I)

* CIEDs and Cell Phones, Electronic security systems and Music Players: practical guidelines

**A. Romanov** (Novosibirsk, Russian Federation)

* How to manage EMI risk in our more and more magnetic waves era? The point of view of Manufacturers

**A. Fischer** (Los Angeles-CA, USA)

* Are MRI conditional devices conditional also for environmental EMI?

**G. Sgarito** (Palermo, I)

Thursday, December 2

**9:00-10:30**

**FORUM ON AF: CLINICAL ISSUES**

Chairs: **A. Altun** (Istanbul, TR)  
**S. Themistoclakis** (Mestre-VE, I)

* Is Sport a risk factor for AF?

**P. Chevalier** (Lyon, F)

* Association Between Atrial Fibrillation and Dementia in the General Population  
  **R. Proietti** (Trento, I)
* Does adherence to treatment guidelines for rhythm control of atrial fibrillation impact on patient outcomes?

**TBA**

* Does adherence to treatment guidelines for rate control of atrial fibrillation impact on patient outcomes?

**C. De Asmundis** (Brussels, B)

* Impact of Atrial Ectopies on the Risk of Stroke  
  **C. Esposito** (Salerno, I)

* AF burden: when to start OAC?

**F. De Sensi** (Grosseto, I)

Friday, December 2

**11:00-12:30**

**HOW TO MANAGE MRI SCAN OF CIEDs PATIENTS**

Chairs: **R. Keegan** (Buenos Aires, RA)  
**R. Vijayvergiya** (Chandigarh, IND)

* Clinical safety of MRI conditional pacemaker system in patients subjected to MRI scan: are there differences according scanned region?  
  **M.L. Narducci** (Rome, I)
* Primary Results on safety of full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator

**N. Neminuschiy** (Moscow, Russian Federation)

* Scanning MRI conditional devices: protocols

**C. Lanzillo** (Rome, I)

* MRI scan in patients with abandoned leads

**F. Quartieri** (Reggio Emilia, I)

* MRI scan of implantable devices: difference between cardiologist and radiologist present guidelines

**TBA**

* MRI scan of patients with S-ICD

**G. Coppola** (Palermo, I)